Praxis Precision Medicines, Inc
PRAX
Positions held
Your positionsPRAX isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Praxis Precision Medicines is positioned in the biotechnology sector, focusing on innovative treatments for neurological diseases, which presents significant growth potential as the demand for effective therapies increas
- The company's market capitalization stands at approximately $7.82 billion, indicating strong investor interest and confidence in its future prospects.
- Despite recent financial challenges, the recommendation for PRAX is a strong buy, suggesting that analysts see potential for recovery and growth.
- The company has not generated any revenue in recent quarters, which raises concerns about its ability to sustain operations and fund research and development.
- In the last reported quarter, PRAX recorded a net income loss of $83.72 million, reflecting ongoing financial difficulties.
- The operating income has consistently been negative, with a loss of $96.904 million in the latest quarter, highlighting the company's struggles to achieve profitability.
Fundamentals
| Market cap | $7.36B | Enterprise value | $6.60B | Trailing P/E | — | Forward P/E | -28.20 |
| PEG | — | Price / book | 5.49 | Beta | 2.81 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -38.9% | ROA | -25.7% | Debt / equity | 0.00 |
| Current ratio | 15.73 | Free cash flow | -$199.44M | Analyst recommendation | strong_buy | Mean target | $644.42 |
| 52w high | $392.70 | 52w low | $50.56 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — | — |
| Net income | -$83.7M | -$92.6M | -$88.9M | -$73.9M | -$71.1M |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$96.9M | -$106M | -$97.0M | -$78.4M | -$76.1M |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $8.6M | $2.4M | $0.0M | — |
| Op margin | — | -2340.3% | -5164.4% | — | — |
| Net income | -$303M | -$183M | -$123M | -$214M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$326M | -$200M | -$126M | -$215M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-02 · Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-03 · Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-08-17 · Praxis Precision Medicines Could Be Approaching 'Perfect Trifecta,' Oppenheimer Says
2026-08-13 · Praxis (PRAX) Q2 2026 Earnings Call Transcript
2026-08-11 · 4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year
2026-08-08 · Is Praxis (PRAX) Trading Bigger Losses for Long-Run CNS Ambition With Its Cash War Chest?
2026-08-07 · RBC Adjusts PT on Praxis Precision Medicines to $462 From $449, Keeps Outperform Speculative Risk Rating
2026-08-07 · Deutsche Bank Adjusts Praxis Precision Medicines PT to $475 From $374, Maintains Buy Rating
2026-08-07 · Praxis Precision Medicines, Inc. Q2 2026 Earnings Call Summary
2026-08-07 · Praxis Precision Medicines Q2 Earnings Call Highlights
2026-08-06 · Praxis Precision Medicines Inc (PRAX) (Q2 2026) Earnings Call Highlights: FDA Approvals on ...
2026-08-06 · Insmed Catapults 34%, Leading A Biotech Rally. But Mirum Takes A Bath.
Price (daily)
Full chart · RSI · MACD · patterns